You are here
Development of Glioblastoma-Targeting Endofullerenes for Imaging Brain Tumors
Email: submissions@lunainnovations.com
DESCRIPTION (provided by applicant): Malignant gliomas, including astrocytic, oligodendrological, or ependymal, account for approximately 70% all brain cancers. The most common form, glioblastoma multiform, remains the deadliest form of glioma. Image-guide
d interventions link imaging of tumors to interventions. Magnetic Resonance Imaging (MRI) using contrast agents is one type of imaging agent critical for all phases in the diagnosis, evaluation and treatment of these lesions. However, current imaging agent
s are limited in their effectiveness based on several problems. Therefore, new integrated agents are needed that combine improved imaging sensitivities with intervention strategies that improve diagnoses and outcomes. Luna Nanoworks has developed novel g
adolinium (Gd)-containing C60 endohedral metallofullerenes (Gd3N C80) that can serve as a platform for developing integrated, image-guidance systems. The goal of this proposal is to develop an image-guided system that would allow for specific tumor targeti
ng capabilities integrated with improved imaging capabilities. We will use Luna Innovations proprietary Gd3N C80 molecules, which are demonstrably more sensitive compared to current imaging agents, as a platform which can be derivatized and functionalized
with various therapeutics and/or agents that improve treatments. We hypothesize that the Gd3N C80 nanoparticles can be produced in sufficient enough quantities to be chemically modified with molecules that will increase their solubility, uptake into glioma
tumor cells, and improve tumor visualization. To test this hypothesis we will first synthesize and characterize the Gd3N C80- derivatives as glioma-targeting endohedrals (GTE) with functional groups that will enhance tumor targeting and visualization. Nex
t we will examine the cellular uptake of GTE using glioblastoma cell lines. The combination of anatomical imaging and dynamic contrast data will allow us to establish a baseline to use the glioma-targeting Gd3N C80 for the development and optimization of f
ully integrated cancer imaging, monitoring, and therapy systems. PUBLIC HEALTH RELEVANCE: Cancers of the brain such as glioblastoma multiform are difficult to diagnose and treat. Luna Nanoworks has developed nanomaterials that have superior diagnostic capa
bilities compared to current agents. We will use these molecules as a platform for developing integrated, image-guidance systems that will improve in the diagnosis and treatment of cancers of the brain.
* Information listed above is at the time of submission. *